OperaV1, PascalFrancis, Corpus, bibRecord, 000438

Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes

Identifieur interne : 000438 ( PascalFrancis/Corpus ); précédent : 000437; suivant : 000439

Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes

Auteurs : Seppo M. Pöykkö ; Eija Kellokoski ; Sohvi Hörkkö ; Heikki Kauma ; Y. Antero Kes Niemi ; Olavi Ukkola

Source :

Diabetes : (New York, NY) [ 0012-1797 ] ; 2003.

RBID : Pascal:04-0353799

Descripteurs français

Pascal (Inist)
- Insuline, Résistance tissu cible, Prévalence, Diabète type 2, Endocrinopathie, Hypertension artérielle, Ghréline.

English descriptors

KwdEn :
- Endocrinopathy, Ghrelin, Hypertension, Insulin, Prevalence, Target tissue resistance, Type 2 diabetes.

Abstract

Experimental studies have suggested that ghrelin plays a role in glucose homeostasis and in the regulation of blood pressure (BP). We therefore assessed the hypothesis that a low ghrelin concentration may be a risk factor for type 2 diabetes and hypertension. We also characterized the effect of the ghrelin Arg51Gln and Leu72Met mutations on ghrelin concentrations in the population-based hypertensive (n = 519) and control (n = 526) cohorts of our OPERA (Oulu Project Elucidating Risk of Atherosclerosis) study. The fasting plasma ghrelin concentrations of 1,040 subjects were analyzed using the radioimmunoassay method. Insulin sensitivity was assessed using the quantitative insulin sensitivity check index (QUICKI). Ghrelin concentrations were negatively associated with fasting insulin (P < 0.001), systolic (P = 0.026) and diastolic BP (P = 0.018), and the prevalence of type 2 diabetes (P = 0.015) and insulin resistance (P < 0.001) in the multivariate models. In the control cohort, low ghrelin was associated with hypertension (BP >140/90 mmHg) (P = 0.031). The subjects with the ghrelin 51Gln allele had lower ghrelin concentrations than the Arg51Arg homozygotes (P = 0.001). We conclude that low ghrelin is independently associated with type 2 diabetes, insulin concentration, insulin resistance, and elevated BP. Therefore, it might have some role in the etiology of type 2 diabetes and the regulation of BP. The ghrelin Arg51Gln mutation is associated with low plasma ghrelin concentrations.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0012-1797`
A02	`01`			`@0 DIAEAZ`
A03		`1`		`@0 Diabetes : (N.Y. NY)`
A05				`@2 52`
A06				`@2 10`
A08	`01`	`1`	`ENG`	`@1 Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes`
A11	`01`	`1`		`@1 PÖYKKÖ (Seppo M.)`
A11	`02`	`1`		`@1 KELLOKOSKI (Eija)`
A11	`03`	`1`		`@1 HÖRKKÖ (Sohvi)`
A11	`04`	`1`		`@1 KAUMA (Heikki)`
A11	`05`	`1`		`@1 KESÄNIEMI (Y. Antero)`
A11	`06`	`1`		`@1 UKKOLA (Olavi)`
A14	`01`			`@1 Department of Internal Medicine and Biocenter Oulu, University of Oulu @2 Oulu @3 FIN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut.`
A20				`@1 2546-2553`
A21				`@1 2003`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 8261 @5 354000113099870130`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 42 ref.`
A47	`01`	`1`		`@0 04-0353799`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Diabetes : (New York, NY)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Experimental studies have suggested that ghrelin plays a role in glucose homeostasis and in the regulation of blood pressure (BP). We therefore assessed the hypothesis that a low ghrelin concentration may be a risk factor for type 2 diabetes and hypertension. We also characterized the effect of the ghrelin Arg51Gln and Leu72Met mutations on ghrelin concentrations in the population-based hypertensive (n = 519) and control (n = 526) cohorts of our OPERA (Oulu Project Elucidating Risk of Atherosclerosis) study. The fasting plasma ghrelin concentrations of 1,040 subjects were analyzed using the radioimmunoassay method. Insulin sensitivity was assessed using the quantitative insulin sensitivity check index (QUICKI). Ghrelin concentrations were negatively associated with fasting insulin (P < 0.001), systolic (P = 0.026) and diastolic BP (P = 0.018), and the prevalence of type 2 diabetes (P = 0.015) and insulin resistance (P < 0.001) in the multivariate models. In the control cohort, low ghrelin was associated with hypertension (BP >140/90 mmHg) (P = 0.031). The subjects with the ghrelin 51Gln allele had lower ghrelin concentrations than the Arg51Arg homozygotes (P = 0.001). We conclude that low ghrelin is independently associated with type 2 diabetes, insulin concentration, insulin resistance, and elevated BP. Therefore, it might have some role in the etiology of type 2 diabetes and the regulation of BP. The ghrelin Arg51Gln mutation is associated with low plasma ghrelin concentrations.
C02	`01`	`X`		`@0 002B21E01A`
C02	`02`	`X`		`@0 002B12B05A`
C03	`01`	`X`	`FRE`	`@0 Insuline @5 01`
C03	`01`	`X`	`ENG`	`@0 Insulin @5 01`
C03	`01`	`X`	`SPA`	`@0 Insulina @5 01`
C03	`02`	`X`	`FRE`	`@0 Résistance tissu cible @5 02`
C03	`02`	`X`	`ENG`	`@0 Target tissue resistance @5 02`
C03	`02`	`X`	`SPA`	`@0 Resistencia tejido blanco @5 02`
C03	`03`	`X`	`FRE`	`@0 Prévalence @5 03`
C03	`03`	`X`	`ENG`	`@0 Prevalence @5 03`
C03	`03`	`X`	`SPA`	`@0 Prevalencia @5 03`
C03	`04`	`X`	`FRE`	`@0 Diabète type 2 @2 NM @5 04`
C03	`04`	`X`	`ENG`	`@0 Type 2 diabetes @2 NM @5 04`
C03	`04`	`X`	`SPA`	`@0 Diabetes de tipo 2 @2 NM @5 04`
C03	`05`	`X`	`FRE`	`@0 Endocrinopathie @5 07`
C03	`05`	`X`	`ENG`	`@0 Endocrinopathy @5 07`
C03	`05`	`X`	`SPA`	`@0 Endocrinopatía @5 07`
C03	`06`	`X`	`FRE`	`@0 Hypertension artérielle @5 09`
C03	`06`	`X`	`ENG`	`@0 Hypertension @5 09`
C03	`06`	`X`	`SPA`	`@0 Hipertensión arterial @5 09`
C03	`07`	`X`	`FRE`	`@0 Ghréline @4 CD @5 96`
C03	`07`	`X`	`ENG`	`@0 Ghrelin @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Hormone pancréatique @5 20`
C07	`01`	`X`	`ENG`	`@0 Pancreatic hormone @5 20`
C07	`01`	`X`	`SPA`	`@0 Hormona pancreática @5 20`
C07	`02`	`X`	`FRE`	`@0 Appareil circulatoire pathologie @5 21`
C07	`02`	`X`	`ENG`	`@0 Cardiovascular disease @5 21`
C07	`02`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 21`
N21				`@1 208`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 04-0353799 INIST
ET :	Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes
AU :	PÖYKKÖ (Seppo M.); KELLOKOSKI (Eija); HÖRKKÖ (Sohvi); KAUMA (Heikki); KESÄNIEMI (Y. Antero); UKKOLA (Olavi)
AF :	Department of Internal Medicine and Biocenter Oulu, University of Oulu/Oulu/Finlande (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Diabetes : (New York, NY); ISSN 0012-1797; Coden DIAEAZ; Etats-Unis; Da. 2003; Vol. 52; No. 10; Pp. 2546-2553; Bibl. 42 ref.
LA :	Anglais
EA :	Experimental studies have suggested that ghrelin plays a role in glucose homeostasis and in the regulation of blood pressure (BP). We therefore assessed the hypothesis that a low ghrelin concentration may be a risk factor for type 2 diabetes and hypertension. We also characterized the effect of the ghrelin Arg51Gln and Leu72Met mutations on ghrelin concentrations in the population-based hypertensive (n = 519) and control (n = 526) cohorts of our OPERA (Oulu Project Elucidating Risk of Atherosclerosis) study. The fasting plasma ghrelin concentrations of 1,040 subjects were analyzed using the radioimmunoassay method. Insulin sensitivity was assessed using the quantitative insulin sensitivity check index (QUICKI). Ghrelin concentrations were negatively associated with fasting insulin (P < 0.001), systolic (P = 0.026) and diastolic BP (P = 0.018), and the prevalence of type 2 diabetes (P = 0.015) and insulin resistance (P < 0.001) in the multivariate models. In the control cohort, low ghrelin was associated with hypertension (BP >140/90 mmHg) (P = 0.031). The subjects with the ghrelin 51Gln allele had lower ghrelin concentrations than the Arg51Arg homozygotes (P = 0.001). We conclude that low ghrelin is independently associated with type 2 diabetes, insulin concentration, insulin resistance, and elevated BP. Therefore, it might have some role in the etiology of type 2 diabetes and the regulation of BP. The ghrelin Arg51Gln mutation is associated with low plasma ghrelin concentrations.
CC :	002B21E01A; 002B12B05A
FD :	Insuline; Résistance tissu cible; Prévalence; Diabète type 2; Endocrinopathie; Hypertension artérielle; Ghréline
FG :	Hormone pancréatique; Appareil circulatoire pathologie
ED :	Insulin; Target tissue resistance; Prevalence; Type 2 diabetes; Endocrinopathy; Hypertension; Ghrelin
EG :	Pancreatic hormone; Cardiovascular disease
SD :	Insulina; Resistencia tejido blanco; Prevalencia; Diabetes de tipo 2; Endocrinopatía; Hipertensión arterial
LO :	INIST-8261.354000113099870130
ID :	04-0353799

Links to Exploration step

Pascal:04-0353799

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes</title>
<author><name sortKey="Poykko, Seppo M" sort="Poykko, Seppo M" uniqKey="Poykko S" first="Seppo M." last="Pöykkö">Seppo M. Pöykkö</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kellokoski, Eija" sort="Kellokoski, Eija" uniqKey="Kellokoski E" first="Eija" last="Kellokoski">Eija Kellokoski</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Horkko, Sohvi" sort="Horkko, Sohvi" uniqKey="Horkko S" first="Sohvi" last="Hörkkö">Sohvi Hörkkö</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kauma, Heikki" sort="Kauma, Heikki" uniqKey="Kauma H" first="Heikki" last="Kauma">Heikki Kauma</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kes Niemi, Y Antero" sort="Kes Niemi, Y Antero" uniqKey="Kes Niemi Y" first="Y. Antero" last="Kes Niemi">Y. Antero Kes Niemi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ukkola, Olavi" sort="Ukkola, Olavi" uniqKey="Ukkola O" first="Olavi" last="Ukkola">Olavi Ukkola</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0353799</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 04-0353799 INIST</idno>
<idno type="RBID">Pascal:04-0353799</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000438</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes</title>
<author><name sortKey="Poykko, Seppo M" sort="Poykko, Seppo M" uniqKey="Poykko S" first="Seppo M." last="Pöykkö">Seppo M. Pöykkö</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kellokoski, Eija" sort="Kellokoski, Eija" uniqKey="Kellokoski E" first="Eija" last="Kellokoski">Eija Kellokoski</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Horkko, Sohvi" sort="Horkko, Sohvi" uniqKey="Horkko S" first="Sohvi" last="Hörkkö">Sohvi Hörkkö</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kauma, Heikki" sort="Kauma, Heikki" uniqKey="Kauma H" first="Heikki" last="Kauma">Heikki Kauma</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kes Niemi, Y Antero" sort="Kes Niemi, Y Antero" uniqKey="Kes Niemi Y" first="Y. Antero" last="Kes Niemi">Y. Antero Kes Niemi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ukkola, Olavi" sort="Ukkola, Olavi" uniqKey="Ukkola O" first="Olavi" last="Ukkola">Olavi Ukkola</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Diabetes : (New York, NY)</title>
<title level="j" type="abbreviated">Diabetes : (N.Y. NY)</title>
<idno type="ISSN">0012-1797</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Diabetes : (New York, NY)</title>
<title level="j" type="abbreviated">Diabetes : (N.Y. NY)</title>
<idno type="ISSN">0012-1797</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Endocrinopathy</term>
<term>Ghrelin</term>
<term>Hypertension</term>
<term>Insulin</term>
<term>Prevalence</term>
<term>Target tissue resistance</term>
<term>Type 2 diabetes</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Insuline</term>
<term>Résistance tissu cible</term>
<term>Prévalence</term>
<term>Diabète type 2</term>
<term>Endocrinopathie</term>
<term>Hypertension artérielle</term>
<term>Ghréline</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Experimental studies have suggested that ghrelin plays a role in glucose homeostasis and in the regulation of blood pressure (BP). We therefore assessed the hypothesis that a low ghrelin concentration may be a risk factor for type 2 diabetes and hypertension. We also characterized the effect of the ghrelin Arg51Gln and Leu72Met mutations on ghrelin concentrations in the population-based hypertensive (n = 519) and control (n = 526) cohorts of our OPERA (Oulu Project Elucidating Risk of Atherosclerosis) study. The fasting plasma ghrelin concentrations of 1,040 subjects were analyzed using the radioimmunoassay method. Insulin sensitivity was assessed using the quantitative insulin sensitivity check index (QUICKI). Ghrelin concentrations were negatively associated with fasting insulin (P < 0.001), systolic (P = 0.026) and diastolic BP (P = 0.018), and the prevalence of type 2 diabetes (P = 0.015) and insulin resistance (P < 0.001) in the multivariate models. In the control cohort, low ghrelin was associated with hypertension (BP >140/90 mmHg) (P = 0.031). The subjects with the ghrelin 51Gln allele had lower ghrelin concentrations than the Arg51Arg homozygotes (P = 0.001). We conclude that low ghrelin is independently associated with type 2 diabetes, insulin concentration, insulin resistance, and elevated BP. Therefore, it might have some role in the etiology of type 2 diabetes and the regulation of BP. The ghrelin Arg51Gln mutation is associated with low plasma ghrelin concentrations.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0012-1797</s0>
</fA01>
<fA02 i1="01"><s0>DIAEAZ</s0>
</fA02>
<fA03 i2="1"><s0>Diabetes : (N.Y. NY)</s0>
</fA03>
<fA05><s2>52</s2>
</fA05>
<fA06><s2>10</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>PÖYKKÖ (Seppo M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KELLOKOSKI (Eija)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HÖRKKÖ (Sohvi)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>KAUMA (Heikki)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>KESÄNIEMI (Y. Antero)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>UKKOLA (Olavi)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>2546-2553</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>8261</s2>
<s5>354000113099870130</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>42 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0353799</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Diabetes : (New York, NY)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Experimental studies have suggested that ghrelin plays a role in glucose homeostasis and in the regulation of blood pressure (BP). We therefore assessed the hypothesis that a low ghrelin concentration may be a risk factor for type 2 diabetes and hypertension. We also characterized the effect of the ghrelin Arg51Gln and Leu72Met mutations on ghrelin concentrations in the population-based hypertensive (n = 519) and control (n = 526) cohorts of our OPERA (Oulu Project Elucidating Risk of Atherosclerosis) study. The fasting plasma ghrelin concentrations of 1,040 subjects were analyzed using the radioimmunoassay method. Insulin sensitivity was assessed using the quantitative insulin sensitivity check index (QUICKI). Ghrelin concentrations were negatively associated with fasting insulin (P < 0.001), systolic (P = 0.026) and diastolic BP (P = 0.018), and the prevalence of type 2 diabetes (P = 0.015) and insulin resistance (P < 0.001) in the multivariate models. In the control cohort, low ghrelin was associated with hypertension (BP >140/90 mmHg) (P = 0.031). The subjects with the ghrelin 51Gln allele had lower ghrelin concentrations than the Arg51Arg homozygotes (P = 0.001). We conclude that low ghrelin is independently associated with type 2 diabetes, insulin concentration, insulin resistance, and elevated BP. Therefore, it might have some role in the etiology of type 2 diabetes and the regulation of BP. The ghrelin Arg51Gln mutation is associated with low plasma ghrelin concentrations.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B21E01A</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B12B05A</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Insuline</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Insulin</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Insulina</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Résistance tissu cible</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Target tissue resistance</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Resistencia tejido blanco</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Prévalence</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Prevalence</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Prevalencia</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Diabète type 2</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Type 2 diabetes</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Diabetes de tipo 2</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Endocrinopathie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Endocrinopathy</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Endocrinopatía</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Hypertension artérielle</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Hypertension</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hipertensión arterial</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Ghréline</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Ghrelin</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Hormone pancréatique</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Pancreatic hormone</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hormona pancreática</s0>
<s5>20</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>21</s5>
</fC07>
<fN21><s1>208</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 04-0353799 INIST</NO>
<ET>Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes</ET>
<AU>PÖYKKÖ (Seppo M.); KELLOKOSKI (Eija); HÖRKKÖ (Sohvi); KAUMA (Heikki); KESÄNIEMI (Y. Antero); UKKOLA (Olavi)</AU>
<AF>Department of Internal Medicine and Biocenter Oulu, University of Oulu/Oulu/Finlande (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Diabetes : (New York, NY); ISSN 0012-1797; Coden DIAEAZ; Etats-Unis; Da. 2003; Vol. 52; No. 10; Pp. 2546-2553; Bibl. 42 ref.</SO>
<LA>Anglais</LA>
<EA>Experimental studies have suggested that ghrelin plays a role in glucose homeostasis and in the regulation of blood pressure (BP). We therefore assessed the hypothesis that a low ghrelin concentration may be a risk factor for type 2 diabetes and hypertension. We also characterized the effect of the ghrelin Arg51Gln and Leu72Met mutations on ghrelin concentrations in the population-based hypertensive (n = 519) and control (n = 526) cohorts of our OPERA (Oulu Project Elucidating Risk of Atherosclerosis) study. The fasting plasma ghrelin concentrations of 1,040 subjects were analyzed using the radioimmunoassay method. Insulin sensitivity was assessed using the quantitative insulin sensitivity check index (QUICKI). Ghrelin concentrations were negatively associated with fasting insulin (P < 0.001), systolic (P = 0.026) and diastolic BP (P = 0.018), and the prevalence of type 2 diabetes (P = 0.015) and insulin resistance (P < 0.001) in the multivariate models. In the control cohort, low ghrelin was associated with hypertension (BP >140/90 mmHg) (P = 0.031). The subjects with the ghrelin 51Gln allele had lower ghrelin concentrations than the Arg51Arg homozygotes (P = 0.001). We conclude that low ghrelin is independently associated with type 2 diabetes, insulin concentration, insulin resistance, and elevated BP. Therefore, it might have some role in the etiology of type 2 diabetes and the regulation of BP. The ghrelin Arg51Gln mutation is associated with low plasma ghrelin concentrations.</EA>
<CC>002B21E01A; 002B12B05A</CC>
<FD>Insuline; Résistance tissu cible; Prévalence; Diabète type 2; Endocrinopathie; Hypertension artérielle; Ghréline</FD>
<FG>Hormone pancréatique; Appareil circulatoire pathologie</FG>
<ED>Insulin; Target tissue resistance; Prevalence; Type 2 diabetes; Endocrinopathy; Hypertension; Ghrelin</ED>
<EG>Pancreatic hormone; Cardiovascular disease</EG>
<SD>Insulina; Resistencia tejido blanco; Prevalencia; Diabetes de tipo 2; Endocrinopatía; Hipertensión arterial</SD>
<LO>INIST-8261.354000113099870130</LO>
<ID>04-0353799</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000438 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000438 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    OperaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:04-0353799
   |texte=   Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes
}}

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Oct 8 06:48:41 2020

	Serveur d'exploration sur l'opéra
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'opéra

Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes

Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri